24Nov/21

Ushering in a “Raging” Era—Fiercely Competitive Phase III ADCs (part I)

November 24, 2021ReviewADC Therapy, CEACAM5, DM4, Phase III ADCsbioadc

An antibody-drug conjugate (ADC) is composed of an antibody, a chemical linker, and a small molecular payload, and takes advantage of the specific targeting binding ability of antibody to transport cytotoxic payloadRead More…

08Jul/21

Analytical methods of average drug to antibody ratio (DAR) of antibody-drug conjugates

July 8, 2021ReviewADCs, DAR analysis, HIC, HILIC, LC-MS, Ultraviolet spectrophotometrybioadc

Antibody-drug conjugate (ADC) is a new type of biological targeting drug for the cancer treatment, which perfectly combines the high specificity of antibody and the strong lethal power of cytotoxin. With theRead More…

08Jul/21

Unprecedented!—FDA accelerates the approval of CD19-ADC

July 8, 2021NewsCD19, CD19-ADC, Loncastuximab tesirinebioadc

Recently, FDA has accelerated the approval of ADC Therapeutics’ targeted CD19-ADC drug Loncastuximab tesirine for the treatment of relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). It is worth mentioning that,Read More…

30Apr/21

How To Design Elite ADCs?

April 30, 2021ReviewADC designbioadc

After more than 20 years of development, ADC drug is becoming the main force in cancer treatment, which, compared with traditional chemotherapy, has a wider application scope. However, minimizing ADCs’ non-target toxicityRead More…

30Apr/21

Immunogenicity, a Headache of ADC Developers

April 30, 2021Antibody-drug Conjugates ResearchADC, Anti-drug antibodybioadc

Protein drugs have the potential to induce immunogenicity, whose consequences may affect the efficacy or even be life-threatening. New models of biotherapy, such as antibody-conjugated (ADC) drugs, fusion proteins, and polyethylene glycolization,Read More…

29Mar/21

Fast-Tracking ADC Drugs Manufacturing and Production Technology

March 29, 2021UncategorizedADC Drugs, Antibody Conjugation Technique, DAR, site-specific conjugation, unnatural amino acid conjugatebioadc

When we get an ideal candidate for ADC, the next step is to consider how to scale it up. This step is important because it is directly related to the post-market marketRead More…

29Mar/21

Overview: Mechanism of Action of ADC

March 29, 2021UncategorizedAction of ADCbioadc

Specific Binding ADC drugs specifically bind to antigenic epitopes of cancer cells through their “guiding” antibodies, and enter into cancer cells through antigen-mediated endocytosis, then release the “warheads” – highly active cytotoxicRead More…

29Mar/21

Comprehensively Review Targets for ADC

March 29, 2021ReviewADC targets, CD19, CD30, CD37, Trop2bioadc

At present, ADC drugs are mainly used in the field of tumors, so antigenic targets are required to be highly expressed in tumor cells but with low or no expression in normalRead More…

31Jan/21

Clinical Results of immunogenicity of Multiple ADC Molecules

January 31, 2021Antibody-drug Conjugates Research, NewsADA, ADCs, Anti-drug antibodybioadc

Protein drugs have high risks of inducing immunogenicity, which may affect the efficacy or even be life-threatening. Most biotherapies, such as antibody-drug conjugates (ADCs), fusion proteins, and polyethylene glycolization, carry unnatural humanRead More…

16Dec/20

Booming 2020 for ADC—Achieved $40 billion Trade

December 16, 2020UncategorizedADC, ADC trade, HER2, HER3, Trop-2bioadc

ADC drugs are undoubtedly the focus of many pharmaceutical companies competing for layout in 2020, reaching $40 billion deal in less than a year. AstraZeneca built a partnership with the Daiichi SankyoRead More…